STAT |
Sanofi and Regeneron encounter more payer resistance over new …
STAT Once again, Sanofi and Regeneron Pharmaceuticals are running into roadblocks trying to win over payers with their new drug for severe eczema. This time a U.K. government watchdog decided the drug would not be cost effective. Sanofi makes double EU filing for cancer and asthma drugs Sanofi responds to draft NICE guidance for its innovative atopic dermatitis drug Dupixent® ? (dupilumab)[i] Regeneron And Sanofi Say EMA Accepts For Review Application For DUPIXEN |
Tag Archives: payer
AMA President Calls on Payer Partners to Curb Type 2 Diabetes
The American Medical Association (AMA) is working to prevent new cases of type 2 diabetes—a leading cause of death and disability in the U.S. However, we know that we cannot do it alone.
Managed Healthcare Executive – Health Management
Five rules for payer success in oncology
Payers must reinvent efforts to reduce cancer cost and increase quality for a value-based care world. Here’s five rules to follow.
Managed Healthcare Executive – Health Management